Vlagatelj bo predstavil rezultate načrtovanega kliničnega preskušanja faze I/ II (protokol je v pregledu pri NCI), katerega cilj je izločiti možnost, da lahko bortezomib poveča tveganje za amiliodozo in/ ali vpliva na njeno poslabšanje in izraženost.
The applicant will present the results from the planned Phase I/ II clinical trial (protocol under review at NCI) aimed at ruling out the possibility that secondary to proteasome inhibition bortezomib treatment may increase the risk of amyloidosis and/ or may have an adverse impact on its progression and organ manifestations.